Market revenue in 2023 | USD 142.7 million |
Market revenue in 2030 | USD 228.0 million |
Growth rate | 6.9% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase III |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III |
Key market players worldwide | Almac Group, Catalent Inc, Waldencast PLC Class A, PCI Technology, Sharp Corp, Thermo Fisher Scientific Inc, PAREXEL, Marken, KLIFO, BioCair |
Phase iii was the largest segment with a revenue share of 53.82% in 2023. Horizon Databook has segmented the Germany clinical trial supplies market based on phase i, phase ii, phase iii covering the revenue growth of each sub-segment from 2018 to 2030.
Germany is one of the major sites for clinical trials along with the UK in Europe. Advancements in technology and availability of high-quality clinical resources are some of the main factors responsible for the growth of this market.
High overhead cost is a major challenge, hence, developing countries are being considered for this market. Clinical supplies providers such as PAREXEL International Corporation dominate the market.
In 2014, PAREXEL International Corporation opened a new distribution center and coordination hub in Berlin, Germany to expand its access to European countries and provide support to clinical trials conducted in Germany.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account